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Case report: DNA testing resolves
unusual serologic results in the
Dombrock system
D. MACFARLAND, K. HUE-ROYE, S. CARTER, D. MOREAU, J. BARRY, M.K. MOULDS, C. LOMAS-FRANCIS,AND M.E. REID
Typing for antigens in the Dombrock blood group system and
identifying the corresponding antibodies are notoriously difficult
tasks. The reagents are scarce and the antibodies are weakly
reactive. When RBCs from family members of a patient with an
antibody to a high-prevalence Dombrock antigen were tested for
compatibility,an unusual pattern of inheritance was observed:RBCs
from the patient’s children and one niece, in addition to those from
some of the patient’s siblings, were compatible. This prompted the
performance of DNA-based assays for DO alleles and the results
obtained were consistent with and explained the compatibility test
results. It was possible to study this large kindred because of the
cooperation of family members, hospital personnel, and reference
laboratory staff. Immunohematology 2006;22:69–71.
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Antibodies to antigens in the Dombrock blood
group system are likely to be more clinically significant
than is currently documented. This is because of the
lack of typed RBCs on antibody identification panels, a
dearth of monospecific antibodies with a reasonable
strength of reactivity, and the absence of in vitro
characteristics that are usually associated with delayed
hemolytic transfusion reactions.1 The cloning of the
gene for Dombrock and the identification of the
molecular basis associated with Dombrock antigens
provide other means by which to study them.2–5
The DOA and DOB alleles can be distinguished by
a mutation at nucleotide (nt) 793(A>G) of DO, which is
predicted to encode a change of Asn265Asp. The Hy–
phenotype is associated with a change of G>T at nt 323
(Gly108Val). The HY allele also carries 793G, which
explains why the Hy– phenotype is invariably
Do(a–b+). The Jo(a–) phenotype, encoded by JO, is
associated with a single-nucleotide change of 350 C>T
(Thr117Ile). 350T is on an allele carrying 793A and
most Jo(a–) phenotype RBCs are Do(a+).1
We describe here the use of PCR amplification
followed by restriction fragment length polymorphism
(RFLP) analyses to resolve unusual serologic results in
a patient with an antibody to a high-prevalence
Dombrock antigen.
Case Report
A 55-year-old, group B, D+ African American
woman was hospitalized with congestive heart failure
(CHF) and anemia. Her antibody screen was negative
and she received two RBC transfusions and was
discharged with a Hct of 29.6%. Tests performed to
identify the cause of the anemia were within the
normal range for each test and there were no signs of
bleeding or hemolysis. Eight days later, the patient was
readmitted with CHF and a Hct of 27%. Two units were
ordered but the antibody screen was positive (2+) by
the IAT. The antibody reacted with all RBCs tested
except a Hy– sample. After 6 days in the hospital, she
was discharged with a Hct of 24.7%. Twelve days later,
she was readmitted with CHF again, chronic renal
failure, and unstable angina. While the antibody was
being investigated, the primary care physician was
informed that compatible blood was not available and
was asked to determine if the patient had siblings. The
patient’s son arranged for five siblings and 13 other
relatives to have blood samples collected for testing
with the patient’s serum. Two ABO-compatible siblings
were crossmatch compatible as were three of her five
children and one niece. Compatible blood was
transfused without incident. Difficulties with antibody
identification, lack of sufficient volumes of anti-Hy and
anti-Joa, and the unusual inheritance pattern prompted
us to perform DNA analysis.
Materials and Methods
Blood samples were collected from consenting
family members. The IATs were performed by
hemagglutination in tubes.
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Genomic DNA was extracted using the QIAamp
DNA Mini Blood Kit (QIAGEN,Valencia, CA). PCR was
performed using the following conditions: 100 ng of
each primer, 200 µM of each dNTP, 2.5mM (for nt 323
and nt 350 of DO) or 3.0mM MgCl2 (for nt 793 of DO),
1.0 U HotStar Taq DNA polymerase (QIAGEN), and
buffer in a total volume of 50 µl. Amplification was
performed in the 9700 thermal cycler (Perkin Elmer,
Norwalk, CT) with the following profile: 95°C for 15
minutes; followed by 35 cycles of 94°C for 20 seconds;
55°C (for nt 323 and nt 350 of DO) or 62°C (for nt 793
of DO) for 20 seconds and 72°C for 20 seconds; then
72°C for 7 minutes.5 PCR products were analyzed by
electrophoresis in 1% agarose gel.
PCR-RFLP assays for these three polymorphisms
were performed using BsaJI for the polymorphism at
nt 323,XcmI for the polymorphism at nt 350,and BseRI
for the DOA/DOB polymorphism
at nt 793.3,6 The sequence of
primers, PCR annealing tempera-
ture, restriction enzyme used to
digest each PCR-amplified pro-
duct, and expected restriction-
fragment sizes are given in 
Table 1. Digested products were
analyzed by electrophoresis on
an 8% polyacrylamide gel.
Results
The results of PCR-RFLP
analyses of the three DO single
nucleotide polymorphisms
(SNPs) are shown in Table 2. The
patient (II-10), who had one HY
and one JO allele, is predicted to
have the phenotype Do(a+Wb+W)
Hy+W Jo(a–) and to have
produced anti-Joa. Her two
compatible siblings (II-4 and II-7)
and one compatible child (III-9)
were JO/JO. The other two compatible children (III-8
and III-11) were HY/JO and the compatible niece (III-
2) was HY/HY. Thus, RBCs from all six compatible
family members are predicted to be Jo(a–). Of the ABO-
compatible but crossmatch-incompatible family
members, each had one DOA or DOB allele together
with either an HY or a JO allele. A summary of ABO
types, compatibility testing with the patient’s serum by
the IAT, and DO alleles is given in the pedigree (Fig. 1).
Discussion
The cooperation among family members, hospital
personnel, and reference laboratory staff made it
possible not only to provide blood for the patient but
also to study this large kindred by PCR-based methods.
The presence of combinations of DOA, DOB, HY, and
JO alleles was consistent with the compatibility testing
Table 1. Primers used for PCR-RFLP analyses
Restriction fragment size
Primer Sequence 5´ to 3´ Uncut size Restriction enzyme (nt) (allele)
DoF TACCTCACCTCAGCAATCCAGCTGCTGAGGAGAGAC 368 bp BseR I (nt 793) 326, 42 268, 58, 42
DoR TTTAGCAGCTGACAGTTATATGTGCTCAGGTTCC (DOA) (DOB)
(annealing temperature 62°C)
DoX2F TCAGTACCAAGGCTGTAGCA 
Do378R AGTAAAGTCAGAATGAACATTGCTGCACAAT 220 bp BsaJ I (nt 323) 120, 92, 8 212, 8 
(annealing temperature 58°C) (wild type) (HY)
Xcm I (nt 350) 167, 53 220
(wild type) (JO)
Table 2. Results of PCR-RFLP analyses
323 (G>T) 350 (C>T) 793 (A>G)
Identification Hy+>Hy– Jo(a+)>Jo(a–) Doa/Dob Alleles Predicted phenotype
II-2 G T A JO/JO Do(a+b–) Hy+ Jo(a–)
II-4 G T A JO/JO Do(a+b–) Hy+ Jo(a–)
II-6 G/T C A/G DOA/HY Do(a+b+W) Hy+W Jo(a+W)
II-7 G T A JO/JO Do(a+b–) Hy+ Jo(a–)
II-9 G/T C A/G DOA/HY Do(a+b+W) Hy+W Jo(a+W)
II-10 G/T C/T G/A HY/JO Do(a+Wb+W) Hy+W Jo(a–)
II-11 G C/T G/A DOB/JO Do(a+ W b+) Hy+ Jo(a+W)
III-1 G C/T G/A DOB/JO Do(a+ W b+) Hy+ Jo(a+W)
III-2 T C G HY/HY Do(a–b+W) Hy– Jo(a–)
III-4 G/T C/T G/A HY/JO Do(a+Wb+W) Hy+W Jo(a–)
III-5 G C/T G/A DOB/JO Do(a+Wb+) Hy+ Jo(a+W)
III-6 G/T C G DOB/HY Do(a–b+) Hy+ Jo(a+W)
III-8 G/T C/T G/A HY/JO Do(a+Wb+W) Hy+W Jo(a–)
III-9 G T A JO/JO Do(a+b–) Hy+ Jo(a–)
III-11 G/T C/T G/A HY/JO Do(a+Wb+W) Hy+W Jo(a–)
III-12 G C/T G/A DOB/JO Do(a+Wb+) Hy+ Jo(a+W)
IV-1 G/T C G DOB/HY Do(a–b+) Hy+W Jo(a+W)
IV-2 G/T C G DOB/HY Do(a–b+) Hy+W Jo(a+W)
IV-3 G C/T G/A DOB/JO Do(a+Wb+) Hy+ Jo(a+W)
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DNA testing of a Jo(a–) kindred
results and provided an explanation for the initial,
apparently unusual inheritance pattern of compatible
donors. This study also revealed a surprisingly high
number of negative alleles (HY or JO or both) in one
kindred.
The Do status of the RBC samples could not be
determined because of the lack of appropriate
antibodies. This study highlights the value of using
PCR-based analyses in conjunction with classic
hemagglutination. This is particularly relevant when
studying blood group antigens that are expressed
weakly and when reagents are scarce. As we have
previously advocated,1,7 PCR-based analyses can be
invaluable for typing reagent RBCs and for screening
for antigen-negative donors.
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Fig. 1. Pedigree of the family studied. The ABO and
Rh types and DO alleles are indicated under
the family members who were tested. * =
presumed; NT = not tested. Circles represent
women and squares represent men. Open
symbols indicate serologically compatible
family members, black symbols indicate ABO-
compatible but serologically incompatible
family members, and grey symbols indicate
either ABO-incompatible family members or
those from whom blood samples were not
obtained.
